Cell cycle-related biomarker lineage promotes the malignant progression of recurrent IDH wild-type glioma

Jianbao Xu; Ying Zhang; Wenhua Fan; Wenping Ma; Zhaoshi Bao; Hongjun Wang

doi:10.1007/s12672-025-04121-7

Abstract

This study developed a cell cycle-related signature for predicting the prognosis of recurrent IDH wild-type glioma, and identified a novel biomarker SYCE2, which could be used to assess the response of patients to TMZ.

Affiliated Institutions

Related Publications

Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts

John Hodgson , Ru-Fang Yeh , Amrita Ray +11 more

Development of model systems that recapitulate the molecular heterogeneity observed among glioblastoma multiforme (GBM) tumors will expedite the testing of targeted molecular th...

2009 Neuro-Oncology 151 citations

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

W.K. Alfred Yung , Robert E. Albright , Jeffrey J. Olson +19 more

A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with gliobl...

2000 British Journal of Cancer 929 citations

A novel tool to analyze MRI recurrence patterns in glioblastoma

Wolfgang Wick , Roger Stupp , Anna-Carina Beule +10 more

At least 10% of glioblastoma relapses occur at distant and even contralateral locations. This disseminated growth limits surgical intervention and contributes to neurological mo...

2008 Neuro-Oncology 85 citations

Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome

Richard W. Tothill , Anna V. Tinker , Joshy George +15 more

Abstract Purpose: The study aim to identify novel molecular subtypes of ovarian cancer by gene expression profiling with linkage to clinical and pathologic features. Experimenta...

2008 Clinical Cancer Research 1472 citations

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

M. Brada , Khê Hoang‐Xuan , R. Rampling +13 more

Recurrent glioblastoma multiforme (GBM) is resistant to most therapeutic endeavors, with low response rates and survival rarely exceeding six months. There are no clearly establ...

2001 Annals of Oncology 367 citations

Publication Info

Year: 2025
Type: article
Citations: 0
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Cell cycle-related biomarker lineage promotes the malignant progression of recurrent IDH wild-type glioma

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                    Jianbao Xu, 
                                
                                    Ying Zhang, 
                                
                                    Wenhua Fan
                                
                                et al.
                            
                            (2025). 
                            Cell cycle-related biomarker lineage promotes the malignant progression of recurrent IDH wild-type glioma. 
                            Discover Oncology
                            
                            .
                            https://doi.org/10.1007/s12672-025-04121-7

Identifiers

DOI: 10.1007/s12672-025-04121-7